Larson Financial Group LLC Has $161,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Larson Financial Group LLC reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 26.0% during the third quarter, HoldingsChannel reports. The firm owned 1,401 shares of the company’s stock after selling 492 shares during the quarter. Larson Financial Group LLC’s holdings in Neurocrine Biosciences were worth $161,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Plato Investment Management Ltd boosted its position in Neurocrine Biosciences by 2,481.9% during the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after buying an additional 10,548 shares during the period. Swiss National Bank boosted its position in Neurocrine Biosciences by 1.4% during the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after buying an additional 4,100 shares during the period. KBC Group NV boosted its position in Neurocrine Biosciences by 78.3% during the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after buying an additional 8,332 shares during the period. Tidal Investments LLC boosted its position in Neurocrine Biosciences by 57.8% during the 1st quarter. Tidal Investments LLC now owns 9,542 shares of the company’s stock worth $1,316,000 after buying an additional 3,497 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Neurocrine Biosciences during the 2nd quarter worth approximately $5,848,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Down 1.0 %

Shares of NBIX stock opened at $126.59 on Friday. Neurocrine Biosciences, Inc. has a 12 month low of $110.81 and a 12 month high of $157.98. The firm has a market capitalization of $12.82 billion, a PE ratio of 33.94 and a beta of 0.35. The firm has a fifty day simple moving average of $119.09 and a two-hundred day simple moving average of $131.67.

Wall Street Analyst Weigh In

NBIX has been the topic of several recent research reports. Piper Sandler upgraded shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $131.00 to $159.00 in a research report on Thursday, August 29th. JPMorgan Chase & Co. lifted their target price on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Guggenheim boosted their price target on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. Finally, Citigroup boosted their price target on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.